Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1

Zhengrong Yang, Ellen Hildebrandt, Fan Jiang, Andrei A. Aleksandrov, Netaly Khazanov, Qingxian Zhou, Jianli An, Andrew T. Mezzell, Bala M. Xavier, Haitao Ding, John R. Riordan, Hanoch Senderowitz, John C. Kappes, Christie G. Brouillette, Ina L. Urbatsch

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is an ABC transporter containing two transmembrane domains forming a chloride ion channel, and two nucleotide binding domains (NBD1 and NBD2). CFTR has presented a formidable challenge to obtain monodisperse, biophysically stable protein. Here we report a comprehensive study comparing effects of single and multiple NBD1 mutations on stability of both the NBD1 domain alone and on purified full length human CFTR. Single mutations S492P, A534P, I539T acted additively, and when combined with M470V, S495P, and R555K cumulatively yielded an NBD1 with highly improved structural stability. Strategic combinations of these mutations strongly stabilized the domain to attain a calorimetric Tm > 70 °C. Replica exchange molecular dynamics simulations on the most stable 6SS-NBD1 variant implicated fluctuations, electrostatic interactions and side chain packing as potential contributors to improved stability. Progressive stabilization of NBD1 directly correlated with enhanced structural stability of full-length CFTR protein. Thermal unfolding of the stabilized CFTR mutants, monitored by changes in intrinsic fluorescence, demonstrated that Tm could be shifted as high as 67.4 °C in 6SS-CFTR, more than 20 °C higher than wild-type. H1402S, an NBD2 mutation, conferred CFTR with additional thermal stability, possibly by stabilizing an NBD-dimerized conformation. CFTR variants with NBD1-stabilizing mutations were expressed at the cell surface in mammalian cells, exhibited ATPase and channel activity, and retained these functions to higher temperatures. The capability to produce enzymatically active CFTR with improved structural stability amenable to biophysical and structural studies will advance mechanistic investigations and future cystic fibrosis drug development.

Original languageEnglish
Pages (from-to)1193-1204
Number of pages12
JournalBiochimica et Biophysica Acta - Biomembranes
Volume1860
Issue number5
DOIs
StatePublished - May 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier B.V.

Funding

This work was supported by the Cystic Fibrosis Foundation Therapeutics grants URBATS13XX0 , Brouil08XX0 , Brouil13XX0 , SENDER13XX0 , KAPPES16XX0 and RIORDA07XXO . Flow cytometry analysis and cell sorting was suported by the UAB Comprehensive Flow Cytometry Core National Institutes of Health grants P30 AR048311 and P30 AI027667 . Access to the VP-Capillary DSC was provided by the Biocalorimetry Lab supported by the NIH Shared Instrumentation Grant # 1S10RR026478 and Shared Facility Program of the UAB Comprehensive Cancer Center , Grant # 316851 . We thank Qun Dai and Kevin Macon for technical assistance. We thank the CFTR3D Structure consortium for insightful discussions. This work was supported by the Cystic Fibrosis Foundation Therapeutics grants URBATS13XX0, Brouil08XX0, Brouil13XX0, SENDER13XX0, KAPPES16XX0 and RIORDA07XXO. Flow cytometry analysis and cell sorting was suported by the UAB Comprehensive Flow Cytometry Core National Institutes of Health grants P30 AR048311 and P30 AI027667. Access to the VP-Capillary DSC was provided by the Biocalorimetry Lab supported by the NIH Shared Instrumentation Grant # 1S10RR026478 and Shared Facility Program of the UAB Comprehensive Cancer Center, Grant # 316851. We thank Qun Dai and Kevin Macon for technical assistance. We thank the CFTR3D Structure consortium for insightful discussions.

FundersFunder number
Cystic Fibrosis Foundation TherapeuticsBrouil13XX0, KAPPES16XX0, Brouil08XX0, SENDER13XX0, URBATS13XX0
NIH
UAB Comprehensive Flow Cytometry Core National Institutes of Health
National Institutes of HealthP30 AI027667, P30 AR048311
National Center for Research ResourcesS10RR026478
Cystic Fibrosis Foundation TherapeuticsRIORDA07XXO
Comprehensive Cancer Center, University of Alabama at Birmingham316851

    Keywords

    • ABC transporters
    • ATP hydrolysis
    • CFTR
    • NBD1
    • Protein unfolding
    • Stabilizing mutations
    • Thermal stability

    Fingerprint

    Dive into the research topics of 'Structural stability of purified human CFTR is systematically improved by mutations in nucleotide binding domain 1'. Together they form a unique fingerprint.

    Cite this